Bethan Jones1, Caroline A Flurey2, Susanna Proudman3, Ricardo J O Ferreira4, Marieke Voshaar5, Wijnanda Hoogland6, Hema Chaplin7, Niti Goel8, Merete Lund Hetland9, Catherine Hill3, Bindee Kuriya10, Kate Mather11, Linda Rasch12, Beverley Shea13, Jasvinder A Singh14, Josef S Smolen15, Jose Ap da Silva16, Savia de Souza17, Tanja Stamm18, Paul Studenic19, Maarten de Wit6, Peter Tugwell20, Maarten Boers12. 1. Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom; Academic Rheumatology, Bristol Royal Infirmary, United Kingdom. 2. Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom. Electronic address: Caroline2.Flurey@uwe.ac.uk. 3. Rheumatology Unit, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, South Australia 5000, Australia. 4. Rheumatology department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Health Sciences Research Unit: Nursing (UICISA: E), Escola Superior de Enfermagem de Coimbra, Coimbra, Portugal. 5. Department of Pharmacy, Radboudumc, Nijmegen, the Netherlands; OMERACT Patient Research Partner, the Netherlands. 6. OMERACT Patient Research Partner, the Netherlands. 7. Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom. 8. Duke University School of Medicine, Durham, NC, USA. 9. DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 10. Department of Medicine, University of Toronto. Canada; Mount Sinai Hospital, Toronto, Ontario, Canada. 11. Patient Research Partner, Canada. 12. Department of Epidemiology & Data Science; and Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands. 13. School of Epidemiology and Public Health, University of Ottawa, Ottawa ON, Canada. 14. Medicine Service, VA Medical Center, Birmingham, AL, USA; Department of Medicine at the School of Medicine, University of Alabama at Birmingham (UAB), USA; Department of Epidemiology at the UAB School of Public Health, Birmingham, AL, USA. 15. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria. 16. Institute for Clinical and Biomedical research (iCBR), Faculty of Medicine, University of Coimbra, Portugal. 17. Centre for Rheumatic Diseases, Weston Education Centre, Kings College London, United Kingdom. 18. Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 19. Division of Rheumatology, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Austria. 20. Department of Medicine, University of Ottawa, Ottawa, Canada.
Abstract
OBJECTIVE: To determine how best to incorporate the patient perspective into rheumatoid arthritis remission criteria. METHODS: At OMERACT 2020, several studies, including a longitudinal multi-centre study testing the validity of adding patient-valued domains to the ACR/EULAR criteria, were presented and discussed by the virtual Special Interest Group. RESULTS: Overall consensus was that there is insufficient evidence to change the remission criteria at this point. Future work should focus on measurement of the new domain of independence, clarifying the value of the patient global assessment, and optimizing the input of domains that patients value in the criteria. CONCLUSION: Incorporating the patient perspective into remission criteria should be further explored.
OBJECTIVE: To determine how best to incorporate the patient perspective into rheumatoid arthritis remission criteria. METHODS: At OMERACT 2020, several studies, including a longitudinal multi-centre study testing the validity of adding patient-valued domains to the ACR/EULAR criteria, were presented and discussed by the virtual Special Interest Group. RESULTS: Overall consensus was that there is insufficient evidence to change the remission criteria at this point. Future work should focus on measurement of the new domain of independence, clarifying the value of the patient global assessment, and optimizing the input of domains that patients value in the criteria. CONCLUSION: Incorporating the patient perspective into remission criteria should be further explored.